John Timko, MD
Psychiatry · Wyomissing, PANPI 1700992948
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,516 of the $151,805 with a category attached, or 89.3%. Otsuka America Pharmaceutical, Inc. accounts for 93.3% of it on its own, with 29 other manufacturers making up the rest. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 947 payments — averaging $160.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$142K
- Alkermes, Inc.$1K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$916
- plus $4K from 24 others
What the payments were for
- Consulting fees$7200%
- Speaking & faculty fees$135,51689%
- Travel & lodging$2200%
- Food & beverage$15,05710%
- Education$2920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 211 | $141,677 |
| Alkermes, Inc. | 90 | $1,429 |
| AbbVie(2 entities) | 177 | $1,223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 85 | $1,075 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 72 | $1,039 |
| Lundbeck LLC | 53 | $916 |
| Neurocrine Biosciences, Inc. | 37 | $784 |
| Teva Pharmaceuticals USA, Inc. | 18 | $486 |
| Corium, LLC | 24 | $438 |
| Vanda Pharmaceuticals Inc. | 19 | $393 |
| Axsome Therapeutics, Inc. | 21 | $381 |
| Ironshore Pharmaceuticals Inc. | 16 | $351 |
| E.r. Squibb & Sons, L.L.C. | 31 | $245 |
| Sunovion Pharmaceuticals Inc. | 21 | $228 |
| Almatica Pharma LLC | 11 | $206 |
| Supernus Pharmaceuticals, Inc. | 18 | $192 |
| Johnson & Johnson | 10 | $163 |
| Shire North American Group Inc | 9 | $137 |
| Acadia Pharmaceuticals Inc | 6 | $100 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Adlon Therapeutics L.p. | 2 | $47 |
| Vertical Pharmaceuticals, LLC | 2 | $46 |
| Merck | 2 | $36 |
| Bausch Health US, LLC | 1 | $30 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| Neos Therapeutics, LP | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$139,059
- ARISTADA$485
- ARISTADA INITIO$121
- CAPLYTA$110
How this compares
$151,805 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $104,954 |
| RexultiBrexpiprazole | 44 | $60,807 |
| VraylarCariprazine Hcl | 40 | $55,337 |
| TrintellixVortioxetine Hydrobromide | 68 | $36,169 |
| CaplytaLumateperone Tosylate | 23 | $30,697 |
| Bupropion XlBupropion Hcl | 596 | $15,867 |
| QuviviqDaridorexant Hcl | 32 | $15,737 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $11,804 |
| Lurasidone Hcl | 49 | $10,896 |
| Buspirone Hcl | 490 | $9,020 |
| ExelonRivastigmine | 13 | $8,972 |
| Duloxetine Hcl | 351 | $7,905 |
| Clonazepam | 729 | $7,797 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 155 | $7,321 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 283 | $7,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $784 | $104,95412 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $141,677 | $60,80744 claims |
| AbbVieVraylar | $1,223 | $55,33740 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,075 | $47,97384 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,039 | $30,69723 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $79 | $15,73732 claims |
| Almatica Pharma LLCSertraline Hcl | $206 | $5,334452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Wyomissing
- Robert NelsonWyomissing$2.2M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.